Cargando…

How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial

BACKGROUND: Empagliflozin has been shown to reduce cardiovascular mortality, but the underlying pathogenetic mechanisms are poorly understood. It was previously demonstrated that empagliflozin improved arterial stiffness. METHODS: Our analysis comprising 58 patients with type 2 diabetes mellitus ide...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bosch, Agnes, Ott, Christian, Jung, Susanne, Striepe, Kristina, Karg, Marina V., Kannenkeril, Dennis, Dienemann, Thomas, Schmieder, Roland E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440009/ https://www.ncbi.nlm.nih.gov/pubmed/30922297 http://dx.doi.org/10.1186/s12933-019-0839-8

Ejemplares similares

Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine
por: Ott, Christian, et al.
Publicado: (2021)

Determinants of arterial stiffness in patients with type 2 diabetes mellitus: a cross sectional analysis
por: Staef, Mawadah, et al.
Publicado: (2023)

Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure
por: Pietschner, R., et al.
Publicado: (2021)

Angiotensin pathways under therapy with empagliflozin in patients with chronic heart failure
por: Bosch, Agnes, et al.
Publicado: (2023)

Early vascular parameters in the micro- and macrocirculation in type 2 diabetes
por: Kannenkeril, Dennis, et al.
Publicado: (2018)

Change of renal function after short-term use of cardioprotective agents in patients with type 2 diabetes is not accurately assessed by the change of estimated glomerular filtration rate: an observational study
por: Kolwelter, Julie, et al.
Publicado: (2022)

Renal and intraglomerular haemodynamics in chronic heart failure with preserved and reduced ejection fraction
por: Jung, Susanne, et al.
Publicado: (2021)

Effects of the sodium‐glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure
por: Kolwelter, Julie, et al.
Publicado: (2021)

SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial
por: Karg, M. V., et al.
Publicado: (2018)

Retinal neurodegeneration in patients with end-stage renal disease assessed by spectral-domain optical coherence tomography
por: Jung, Susanne, et al.
Publicado: (2020)

Is vascular remodelling in patients with chronic heart failure exaggerated?
por: Pietschner, Robert, et al.
Publicado: (2022)

A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation
por: Ott, Christian, et al.
Publicado: (2017)

The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial
por: Kolwelter, Julie, et al.
Publicado: (2022)

Retinal Capillary Rarefaction in Patients with Type 2 Diabetes Mellitus
por: Jumar, Agnes, et al.
Publicado: (2016)

Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers
por: Gessner, Arne, et al.
Publicado: (2022)

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
por: Cherney, David ZI, et al.
Publicado: (2014)

Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury
por: Aroor, Annayya R., et al.
Publicado: (2018)

Empagliflozin does not reverse lipotoxicity-induced impairment in human myeloid angiogenic cell bioenergetics
por: Cinquegrani, Gloria, et al.
Publicado: (2022)

Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus
por: Lunder, Mojca, et al.
Publicado: (2018)

Empagliflozin prevents doxorubicin-induced myocardial dysfunction
por: Sabatino, Jolanda, et al.
Publicado: (2020)

The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study
por: Ring, Arne, et al.
Publicado: (2013)

Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy
por: Irace, Concetta, et al.
Publicado: (2018)

Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial
por: Shimizu, Wataru, et al.
Publicado: (2020)

Effect of 3-Month Therapy with Empagliflozin on Ambulatory Blood Pressure and Arterial Stiffness in Patients with Type 2 Diabetes Mellitus
por: Papazafiropoulou, Athanasia K., et al.
Publicado: (2021)

Association of subclinical myocardial injury with arterial stiffness in patients with type 2 diabetes mellitus
por: Yiu, Kai-Hang, et al.
Publicado: (2013)

The Effect of Additional Treatment with Empagliflozin or Semaglutide on Endothelial Function and Arterial Stiffness in Subjects with Type 1 Diabetes Mellitus—ENDIS Study
por: Navodnik, Maja Preložnik, et al.
Publicado: (2023)

Empagliflozin protects the heart against ischemia/reperfusion-induced sudden cardiac death
por: Hu, Zhaoyang, et al.
Publicado: (2021)

Editorial comment: Renal denervation
por: Schmieder, Roland E., et al.
Publicado: (2021)

Impact of glycemic control with sitagliptin on the 2-year progression of arterial stiffness: a sub-analysis of the PROLOGUE study
por: Tomiyama, Hirofumi, et al.
Publicado: (2016)

Aortic propagation velocity does not correlate with classical aortic stiffness parameters in healthy individuals
por: Arı, Hatem, et al.
Publicado: (2017)

Impact of empagliflozin on right ventricular parameters and function among patients with type 2 diabetes
por: Sarak, Bradley, et al.
Publicado: (2021)

Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics
por: Htoo, Phyo T., et al.
Publicado: (2022)

Association of female sex and heart rate with increased arterial stiffness in patients with type 2 diabetes mellitus
por: Kang, Min-Kyung, et al.
Publicado: (2017)

Arterial stiffness is an independent predictor for risk of mortality in patients with type 2 diabetes mellitus: the REBOUND study
por: Kim, Jeong Mi, et al.
Publicado: (2020)

Hypertrophic remodelling of retinal arterioles in patients with congestive heart failure
por: Jung, Susanne, et al.
Publicado: (2021)

Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes
por: Ott, Christian, et al.
Publicado: (2014)

Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome
por: Kusaka, Hiroaki, et al.
Publicado: (2016)

SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
por: Li, Chenguang, et al.
Publicado: (2019)

Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study
por: Gaborit, B., et al.
Publicado: (2021)

The impact of empagliflozin on cardiac physiology and fibrosis early after myocardial infarction in non-diabetic rats
por: Daud, Elias, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fvq6dssiv3afm5ck134fdm0b63